In CML cells, in particular, increased glycolytic activity has been found to depend on the non-hypoxic activation of HIF-1α and has been described as marker for early detection of imatinib resistance, before clinical manifestations [7, 49]. Here, HIF1A is linked to chronic myelogenous leukemia, BCR-ABL1 positive.